A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
Condition: Heart Failure With Preserved Ejection Fraction Interventions: Drug: sacubitril/valsartan; Drug: Enalapril; Drug: Valsartan; Drug: Placebo to match sacubitril/valsartan; Drug: Placebo to match enalapril; Drug: Placebo to match valsartan Sponsor: Novartis Pharmaceuticals Not yet recruiting - verified February 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2017 Category: Research Source Type: clinical trials